<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2305233695
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESCITAM 20 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESCITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        83.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Escitam is an antidepressant which belongs to the &lsquo;SSRI&rsquo; group (selective serotonin reuptake inhibitors). These medicines act on the serotonin-system in the brain by increasing the serotonin level. Disturbances in the serotonin-system are considered an important factor in the development of depression and related diseases.</p><p>Escitam is used to treat:</p><p>&nbsp; &nbsp; &bull; Depressive disorders (episodes of a major depression)</p><p>&nbsp; &bull; Panic disorder with or without agoraphobia (e.g. fear of leaving the house, entering shops, being in crowds and in public places)</p><p>&bull; Social anxiety disorder (social phobia)</p><p>&bull; Obsessive-compulsive disorder</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Escitam</strong></p><p>&bull; if you are allergic to escitalopram or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull; if you take other medicines which belongs to a group called MAO inhibitors, including selegiline (used in the treatment of Parkinson&acute;s disease), moclobemide (used in the treatment of depression) and linezolid (an antibiotic)</p><p>&bull; if you are born with or have had an episode of abnormal heart rhythm (seen at ECG; an examination to evaluate how the heart is functioning)</p><p>&bull; if you take medicines for heart rhythm problems or that may affect the heart&rsquo;s rhythm (see section 2 &ldquo;Other medicines and Escitam&rdquo;)</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Escitam</p><p>Please tell your doctor if you have any other condition or illness, as your doctor may need to take this into consideration. In particular, tell your doctor:</p><p>&bull; if you have epilepsy. Treatment with Escitam should be stopped if seizures occur or if there is an increase in the seizure frequency (see also section 4 &laquo;Possible side effects&raquo;)</p><p>&bull; if you suffer from impaired liver or kidney function. Your doctor may need to adjust your dosage</p><p>&bull; if you have diabetes. Treatment with Escitam may alter glycaemic control. Insulin and/or oral&nbsp;hypoglycaemic dosage may need to be adjusted</p><p>&bull; if you have a decreased level of sodium in the blood&bull; if you have low levels of potassium or magnesium in your blood (hypokalaemia/hypomagnesaemia).</p><p>&bull; if you have a tendency to easily develop bleedings or bruises&bull; if you are receiving electroconvulsive treatment</p><p>&bull; if you have coronary heart disease</p><p>&bull; if you suffer or have suffered from heart problems or have recently had a heart attack</p><p>&bull; if you suffer from a heart condition called &lsquo;QT-prolongation&rsquo; or if the condition runs in your family.</p><p>&bull; if you have a low resting heart-rate and/or you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets)</p><p>&bull; if you experience a fast or irregular heartbeat, fainting, collapse or dizziness on standing up, which may indicate abnormal functioning of the heart rate</p><p>&bull; if you have or have a history of glaucoma.</p><p><strong>Please note</strong></p><p>Some patients with manic-depressive illness may enter into a manic phase. This is characterized by unusual and rapidly changing ideas, inappropriate happiness and excessive physical activity. If you experience this, contact your doctor.</p><p>Symptoms such as restlessness or difficulty to sit or stand still can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.</p><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorder</strong></p><p>If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><p>&bull; If you have previously had thoughts about killing or harming yourself</p><p>&bull; If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant</p><p>If you have thoughts of harming or killing yourself at any time, <strong>contact your doctor or go to a hospital straight away.</strong></p><p><strong>You may find it helpful to tell a relative or close friend </strong>that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p><strong>Children and adolescents</strong></p><p>Escitam should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects such as suicide attempts, suicidal thoughts and hostility (predominately aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Escitam for patients under 18 because he/she decides that this is in their best interest. If your doctor has prescribed Escitam for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any symptoms listed above develop or worsen when patients under 18 are taking Escitam. Also, the long term safety effects concerning growth, maturation and cognitive and behavioural development of Escitam in this age group have not yet been demonstrated.</p><p><strong>Other medicines and Escitam </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>DO NOT TAKE Escitam</strong> if you take medicines for heart rhythm problems or medicines that may affect the heart&rsquo;s rhythm, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarian treatment particularly halofantrine), certain antihistamines (astemizole, mizolastine). If you have any further questions about this you should speak to your doctor.</p><p>Tell your doctor if you are taking any of the following medicines:</p><p>&bull; &rdquo;Non-selective monoamine oxidase inhibitors (MAOIs)&rdquo;, containing phenelzine, iproniazid, isocarboxazid, nialamide, and tranylcypromine as active ingredients. If you have taken any of these medicines you will need to wait 14 days before you start taking Escitam. After stopping Escitam you must allow 7 days before taking any of these medicines</p><p>&bull; &ldquo;Reversible, selective MAO-A inhibitors&rdquo;, containing moclobemide (used to treat depression)</p><p>&bull; &ldquo;Irreversible MAO-B inhibitors&rdquo;, containing selegiline (used to treat Parkinson&rsquo;s disease). These increase the risk of side effects</p><p>&bull; The antibiotic linezolid</p><p>&bull; Lithium (used in the treatment of manic-depressive disorder) and tryptophan</p><p>&bull; Sumatriptan and similar medicines (used to treat migraine) and tramadol (used against severe pain) These increase the risk of side effects</p><p>&bull; Cimetidine and omeprazole (used to treat stomach ulcers), fluvoxamine (antidepressant) and ticlopidine (used to reduce the risk of stroke). These may cause increased blood levels of Escitam</p><p>&bull; St. John&rsaquo;s Wort (hypericum perforatum) - a herbal remedy used for depression</p><p>&bull; Acetylsalicylic acid and non-steroidal anti-inflammatory drugs (medicines used for pain relief or to thin the blood, so called anti-coagulant)</p><p>&bull; Warfarin, dipyridamole, and phenprocoumon (medicines used to thin the blood, so called anti coagulant). Your doctor will probably check the coagulation time of your blood when starting and discontinuing Escitam in order to verify that your dose of anti-coagulant is still adequate</p><p>&bull; Mefloquin (used to treat Malaria), bupropion (used to treat depression and to help you quit smoking) and tramadol (used to treat severe pain) due to a possible risk of a lowered threshold for seizures</p><p>&bull; Neuroleptics (medicines to treat schizophrenia, psychosis) due to a possible risk of a lowered threshold for seizures, and antidepressants</p><p>&bull; Flecainide, propafenone, and metoprolol (used in cardio-vascular diseases) desipramine</p><p>&bull; clomipramine, and nortriptyline (antidepressants) and risperidone, thioridazine, and haloperidol (antipsychotics). The dosage of Escitam may need to be adjusted</p><p>&bull; Medicines that prolong the so-called &lsquo;QT interval&rsquo; or medicines which lower potassium or magnesium levels in the blood. Ask your doctor for advice on these medicines</p><p><strong>Escitam with food, drink and alcohol</strong></p><p>Escitam can be taken with or without food (see section 3 &ldquo;How to take Escitam &rdquo;).</p><p>As with many medicines, combining Escitam with alcohol is not advisable, although Escitam is not expected to interact with alcohol.</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Make sure your midwife and/or doctor know you are on Escitam .When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like Escitam may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>If you take Escitam during the last 3 months of your pregnancy you should be aware that the following effects may be seen in your newborn baby: trouble with breathing, blue-ish skin, fits, body temperature changes, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, vivid reflexes, tremor, jitteriness, irritability, lethargy, constant crying, sleepiness and sleeping difficulties. If your newborn baby has any of these symptoms, please contact your doctor immediately.</p><p>If used during pregnancy Escitam should never be stopped abruptly.</p><p>Do not take Escitam if you are breast-feeding unless you and your doctor have discussed the risks and benefits involved.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><em>Fertility</em></p><p>Citalopram, a medicine like escitalopram, has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet.</p><p><strong>Driving and using machines</strong></p><p>This medicine can alter reaction times severely enough, even when used as indicated, to impair the ability to drive or use machinery. Do not drive a car or operate machinery until you know how Escitam affects you</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Adults</strong></p><p><em>To treat depression</em></p><p>The recommended dose of Escitam is 10 mg taken as one daily dose. The dose can be increased by your doctor to a maximum of 20 mg per day.</p><p><em>To treat panic disorders, with or without agoraphobia</em></p><p>The starting dose of Escitam is 5 mg as one daily dose for the first week before increasing the dose to 10mg per day. The dose may be further increased by your doctor to a maximum of 20 mg per day.</p><p><em>To treat social anxiety disorder (social phobia)</em></p><p>The recommended dose of Escitam is 10 mg taken as one daily dose. Depending on your response to the treatment, your doctor can either decrease your dose to 5 mg per day or increase the dose to a maximum of 20 mg daily.</p><p><em>To treat Obsessive-Compulsive Disorder (OCD)</em></p><p>The recommended dose of Escitam is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg daily. For long-term treatment, the benefits of treatment should be regularly checked.</p><p><em>Elderly patients (above 65 years of age)</em></p><p>The recommended starting dose of Escitam is 5 mg taken as one daily dose. The dose may be increased by your doctor to 10 mg per day.</p><p>The efficacy of Escitam in social anxiety disorder (social phobia) in elderly patients has not been studied.</p><p><em>Patients with impaired liver function</em></p><p>The recommended starting dose of Escitam for patients with impaired liver function should not exceed 5 mg daily in the first 14 days. Your doctor can then raise the daily dose, depending on your response, up to 10 mg daily. Caution and an especially careful&nbsp;dose titration are indicated in patients with severely impaired liver function.</p><p><em>Patients with impaired kidney function</em></p><p>With mild to moderate impairment of kidney function, no dose adjustment is required. Caution is indicated for patients with severely impaired kidney function.</p><p><em>Use in children and adolescents (below 18 years of age)</em></p><p>Escitam should not normally be given to children and adolescents. For further information please see section 2 &ldquo;What you need to know before you take Escitam &rdquo;.</p><p>Escitam 10 and 20 mg film-coated tablets:</p><p>Please take the film-coated tablets once daily, swallowed whole with sufficient fluid (preferably a glass of water). Escitam may be taken with or without food.</p><p><strong><img alt="" width="506" height="180" src="data:image/jpeg;base64,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" />Duration of treatment</strong></p><p>It may take a couple of weeks before you start to feel better. Continue to take Escitam even if it takes some time before you feel any improvement in your condition. Do not change the dose of your medicine without talking to your doctor first.</p><p>Continue to take Escitam for as long as your doctor recommends. If you stop your treatment too soon, your symptoms may return. It is recommended that treatment should be continued for at least 6 months after you feel well again.</p><p><strong>If you take more Escitam than you should.</strong></p><p>If you have taken more&nbsp;than you should, or if someone else has taken your medicine by mistake, inform your doctor or go to a hospital straight away. Do this even if you still feel well. Take any remaining tablets as well as the box/container with you, even if this is empty.</p><p>Symptoms of overdose might include dizziness, shaking, restlessness, feeling sleepy, falling unconscious, change in heart rhythm, fits, hypoventilation, muscle weakness, tenderness or pain and feeling unwell or have a high temperature (rhabdomyolysis), change in body fluid/salt balance, vomiting and being sick.</p><p><strong>If you forget to take Escitam.</strong></p><p>Do not take a double dose to make up for forgotten doses. If you should forget to take a dose of Escitam, just take Escitam as usual the next time.</p><p><strong>If you stop taking Escitam.</strong></p><p>If you want to interrupt the treatment, please discuss this with your doctor beforehand. He might need to take appropriate measures. Do not stop taking the medicine on your own initiative without discussing this with your doctor. When stopping treatment with Escitam , your doctor will gradually reduce your dose over a number of weeks or months. This should help reduce the possibility of withdrawal effects.</p><p>When you stop taking Escitam , especially if it is abruptly, you may feel discontinuation symptoms. These are common when treatment with Escitam is stopped. The risk is higher, when Escitam has been used for a long time or in high doses or when the dose is reduced too quickly. Most people find that the symptoms are mild and go away on their own within two weeks. However, in some patients they may be severe in intensity or they may be prolonged (2-3 months or more). If you get severe discontinuation symptoms when you stop taking Escitam , please contact your doctor. He or she may ask you to start taking your tablets again and come off them more slowly.Discontinuation symptoms include: Feeling dizzy (unsteady or off-balance), feelings like pins and needles, burning sensations and (less commonly) electric shock sensations, including in the head, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling anxious, headaches, feeling sick (nausea) and vomiting, sweating (including night sweats), feeling restless or agitated, tremor (shakiness), feeling confused or disorientated, feeling emotional or irritable, diarrhoea (loose stools), visual disturbances, fluttering or pounding heartbeat (palpitations).</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Side effects most commonly occur in the first or second week of treatment, and normally become less severe and less frequent as treatment continues.</p><p><strong>See your doctor if you get any of the following side effects during treatment:</strong></p><p>Uncommon (more than 1 out of 1000 persons and less than 1 out of 100 persons):</p><p>&bull; Unusual bleeds, including gastrointestinal bleeds</p><p>Rare (more than 1 out of 10000 and less than 1 out of 1000 persons):</p><p>&bull; If you experience swelling of skin, tongue, lips, or face, or have difficulties breathing or swallowing (allergic reaction), contact your doctor or go to a hospital straight away</p><p>&bull; If you have a high fever, agitation, confusion, trembling and abrupt contractions of muscles these may be signs of a rare condition called serotonin syndrome</p><p>If you experience the following side effects you should contact your doctor or go to the hospital straight away:</p><p>&bull; Difficulties urinating</p><p>&bull; Seizures (fits)</p><p>&bull; Yellowing of the skin and the white in the eyes are signs of liver function impairment/hepatitis</p><p>&bull; Fast, irregular heart beat, fainting which could be symptoms of a life-threatening condition known as Torsades de Pointes</p><p><strong>In addition to above the following side effects have been reported:</strong></p><p><u>Very common (more than 1 out of 10 persons):</u></p><p>&bull; Feeling sick (nausea)</p><p>&bull; Headache</p><p><u>Common (more than 1 out of 100 persons and less than 1 out of 10 persons):</u></p><p>&bull; Generalised fear, restlessness, abnormal dreams, difficulty in sleeping, sleepiness, dizziness, a skin sensation, such as burning, prickling, itching, or tingling, with no apparent physical cause, tremor, yawning</p><p>&bull; Sexual disturbances (delayed ejaculation, problem with erection, decreased sexual drive and women may experience difficulties achieving orgasm)</p><p>&bull; Diarrhoea, constipation, vomiting, dry mouth&bull; Blocked or runny nose (sinusitis)</p><p>&bull; Increased sweating&bull; Fatigue, fever&bull; Joint and muscle pain</p><p>&bull; Increased weight</p><p>&bull; Decreased or increased appetite</p><p><u>Uncommon (more than 1 out of 1000 persons and less than 1 out of 100 persons):</u></p><p>&bull; Involuntary grinding or clenching of the teeth, agitation, nervousness, panic attack, confusion state.</p><p>&bull; Taste disturbance, sleep disorder, fainting</p><p>&bull; Nosebleed</p><p>&bull; Bleeding from the uterus that is not associated with menstruation, abnormally heavy or extended menstrual flow</p><p>&bull; Nettle rash (urticaria), rash, itching (pruritus)&bull; Hair loss&bull; Swelling of the arms or legs</p><p>&bull; Enlarged pupils (mydriasis), blurred vision, ringing in the ears (tinnitus)</p><p>Fast heart beat</p><p>&bull; Decreased weight</p><p><u>Rare (more than 1 out of 10000 and less than 1 out of 1000 persons):</u></p><p>&bull; Aggression, depersonalisation, hallucination</p><p>&bull; Slow heartbeat</p><p><u>Some patients have reported (frequency cannot be estimated from the available data):</u></p><p>&bull; Thoughts of harming yourself or thoughts of killing yourself, see also section &ldquo;Warnings and precautions&rdquo;</p><p>&bull; Mania</p><p>&bull; Movement disorders (involuntary movements of the muscles)</p><p>&bull; Flow of milk in women that are not nursing</p><p>&bull; Painful erection of the penis</p><p>&bull; Bleeding disorders including skin and mucous bleeding (ecchymosis) and low level of blood platelets (thrombycytopenia)</p><p>&bull; Dizziness when you stand up due to low blood pressure (orthostatic hypotension)</p><p>&bull; Decreased levels of sodium in the blood (the symptoms are feeling sick and unwell with weak muscles or confused)</p><p>&bull; Increase in the amount of urine excreted (inappropriate ADH secretion)</p><p>&bull; Abnormal liver function test (increased amounts of liver enzymes in the blood)</p><p>&bull; Sudden swelling of the skin and mucosa (angioedemas)</p><p>&bull; Suicide-related events</p><p>&bull; Inability to sit still or remain motionless, feeling of restlessness associated with increased movement*</p><p>&bull; Anorexia*</p><p>&bull; Alteration of the heart rhythm (called &ldquo;prolongation of QT interval&rdquo;, seen on ECG, electrical activity of the heart)</p><p>* These side effects have been reported with drugs that work in a similar way to escitalopram (the active ingredient of Escitam ).</p><p>An increased risk of bone fractures has been observed in patients taking this type of medicines.</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister strips, tablet container and carton after EXP. The expiry date refers to the last day of that month.</p><p>Blister packs: Do not store above 30&ordm;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is escitalopram. Each film-coated tablet contains 10 mg or 20 mg escitalopram (as oxalate).</p><p>The other ingredients are: tablet core:microcrystalline cellulose, colloidal anhydrous silica, croscarmellose sodium, talc, magnesium stearate, coating: hypromellose 6cP, titanium dioxide (E 171), macrogol 6000.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Escitam 10 mg: White, oval, biconvex, 6.4 x 9.25 mm film coated tablets, embossed with ‘E 1’ on one side and a score on one face and two sides.The tablet can be divided into equal halves.
Escitam 20 mg: White, oval, biconvex, 8 x 11.80 mm film coated tablets embossed with ‘E 2’ on one side and a score on one face and two sides. The tablet can be divided into equal halves.
Escitam is obtainable in blister packs of 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AJA Pharmaceutical Industries Company, Ltd.</p><p>Hail Industrial City MODON, Street No 32</p><p>PO Box 6979, Hail 55414</p><p>Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="text-align:justify">إسيتام هو مضاد للإكتئاب ويتبع لمجموعة إس إس آر آي (المثبطات الانتقائية لاسترداد السيروتونين). تعمل هذه الأدوية على نظام السيروتونين في المخ عن طريق زيادة مستوى السيروتونين. تعتبر الاضطرابات في نظاك السيروتونين عاملا في حدوث الاكتئاب والأمراض المرتبطة به.</p><p dir="RTL" style="text-align:justify">يستخدم إسيتام في علاج مايلي:</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; -&nbsp;الاضطرابات الاكتئابية (نوبات الاكتئاب الرئيسي)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; - اضطرابات الهلع سواء كان مع أو بدون الخوف من الأماكن المفتوحة (مثل الخوف من ترك المنزل، دخول الأسواق، التواجد في الزحام وفي الأماكن العامة)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp;- اضطرابات الرهاب الاجتماعي (الخوف الاجتماعي)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp;- اضطراب الوسواس القهري</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>لا تتناول إسيتام في الحالات التالية</strong><strong>:</strong></p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; - إذا كان لديك حساسية للإسيتالوبرام أو أي من مكونات هذا الدواء (انظر في القسم 6)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp;- إذا كنت تتناول أدوية أخرى تتبع لمثبطات مونوأوكسيديز بما في ذلك سيليجلين (يستعمل لعلاج مرض باركنسون) وموكلوبيميد (يستخدم لعلاج الاكتئاب) ولاينزوليد (مضاد حيوي).</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp;- إذا كنت تعاني&nbsp;من أو ومولود مع عدم انتظام في ضربات القلب (وتم إثباتها بجهاز تخطيط القلب، وهو فحص لتقييم كيكفة عمل القلب)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp; إذا كنت تتناول دواء لمشاكل في دقات القلب أو تلك التي تؤثر على دقات القلب (أنظر القسم 2 &quot;إسيتام والأدوية الأخرى&quot;)</p><p dir="RTL" style="text-align:justify"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL" style="text-align:justify">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل تناول إسيتام.</p><p dir="RTL" style="text-align:justify">يرجى إخبار طبيبك إذا كان لديك أي حالة أو مرض آخر حيث أن الطبيب سيأخذ هذا في الاعتبار. وعلى وجه الخصوص:</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp;- إذا كان لديك صرع، يجب عليك التوقف عن تناول إسيتام إذا ظهرت نوبة الصرع أو إذا كان هناك زيادة في معدل تكرار النوبة (أنظر للقسم 4 &quot;الآثار الجانبية المحتملة&quot;)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp;- إذا كنت تعاني من ضعف في وظائف الكبد أو الكلى، قد يحتاج طبيبك لضبط الجرعة.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; - إذا كان لديك انخفاض&nbsp;في مستوى الصوديوم في الدم.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp;&nbsp; &nbsp;- إذا كان لديك انخفاض في البوتاسيوم أو الماغنيسيوم في الدم.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; - إذا كنت في خطر الإصابة بالنزيف والكدمات بسهولة.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; - إذا كنت تتلقى العلاج بالصدمة الكهربائية.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; - إذا كان لديك مرض شريان القلب التاجي.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp;- إذا كنت تعاني أو عانيت من مشاكل في القلب أو تعرضت مؤخرا لنوبة قلبية.</p><p dir="RTL" style="text-align:justify">&nbsp;&nbsp; &nbsp; - إذا كنت تعاني من مرض في القلب يسمى (QT-Prolongation) أو يعاني منه أحد أفراد عائلتك.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp;&nbsp; &nbsp;- إذا كان لديك انخفاض في معدل نزول ضربات القلب عن الراحة (بعد بذل مجهود بدني) و/أو أنك تعرف أنه قد يكون لديك استنزاف أو انخفاض الاملاح كنتيجة للقيء أو إسهال حاد لمدة طويلة (كونك كنت مريض)</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp;&nbsp; - إذا ظهر لديك تسارع في نبضات القلب أو شحوب أو انهيار أو دوار عند الوقوف مما يشير عن تغير غير طبيعي في معدل نبضات القلب.</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; &nbsp; &nbsp;- إذا كان لديك جلوكوما (الماء الأزرق) أو سبق وأن أصبت بها.</p><p dir="RTL" style="text-align:justify"><strong>يرجى ملاحظة</strong><strong>:</strong></p><p dir="RTL" style="text-align:justify">بعض المرضى الذين يعانون من مرض الاكتئاب الهوسي قد يدخلون في مرحلة الهوس ويمكن تمييز ذلك بالتغيير السريع والغير مألوف في الأفكار والفرح في غير وقته والنشاط الجسدي المفرط فإذا تعرضت لمثل هذا، تواصل مع طبيبك.</p><p dir="RTL" style="text-align:justify">الأعراض مثل عدم الراحة أو الصعوبة في الجلوس أو الوقوف قد تحدث أيضا أثناء الأسابيع الأولى من العلاج. أخبر طبيبك فورا في حال تعرضك لهذه الأعراض.</p><p dir="RTL" style="text-align:justify"><strong>الأفكار الانتحارية وتفاقم الاكتئاب أو اضطرابات القلقق</strong></p><p dir="RTL" style="text-align:justify">إذا كنت مكتئبا أو/و لديك اضطراب قلق أو قد يكون لديك في بعض الأوقات أفكار إيذاء أو قتل نفسك. هذه الأعراض قد تزيد عن استخدامك الأولي لمضادات الاكتئاب حيث أن كافة هذه الأدوية تستغرق وقت حتى يظهر مفعولها وعادة ما تكون أسبوعين ولكن أحيانا أكثر.</p><p dir="RTL" style="text-align:justify">قد تكون أقرب للتفكير بذلك كما يلي:</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp; - إذا كانت لديك أفكار سابقة عن قتل أو إيذاء نفسك</p><p dir="RTL" style="text-align:justify">&nbsp; &nbsp;- إذا كنت مراهقا. أظهرت التجارب السريرية زيادة مخاطر السلوك الانتحاري في البالغين لمن هم دون 25 سنة الذين لديهم ظروف نفسية وتم علاجهم بمضاد للاكتئاب.</p><p dir="RTL" style="text-align:justify">إذا ظهرت لديك أفكار سابقة عن قتل أو إيذاء نفسك في أي وقت، تواصل مع طبيبك أو اذهب للمستشفى مباشرة.</p><p dir="RTL" style="text-align:justify"><strong>قد يكون من الأفضل طلب المساعدة من الأقارب أو صديق مقرب</strong> بإبلاغهم بأنك تعاني من اضطراب قلق وأطلب منهم قراءة هذه النشرة الطبية كما يمكنك أن تطلب منهم إبلاغك إذا كانوا يعتقدون أن اكتئابك أو قلقك تطور إلى الأسوأ أو إذا كانوا قلقين من تغيرات في سلوكك.</p><p dir="RTL" style="text-align:justify"><strong>الأطفال والمراهقون</strong></p><p dir="RTL" style="text-align:justify">يتعين عادة عدم استعمال إسيتام للأطفال والمراهقين أقل من ١٨ سنة. كما يتعين أن تعرف أن المرضى أقل ١٨ سنة لديهم مخاطرة أعلى في ظهور الاثار الجانبية مثل محاولات الانتحار والتفكير في الانتحار والعداء (العصبية الغالبة والسلوك المعارض والغضب) عند تناولهم هذا النوع من الأدوية. على الرغم من ذلك، قد يصف الطبيب إسيتام لمرضى دون سن&nbsp;١٨ سنة لأنه قرر أن ذلك ف مصلحتهم. إذا وصف الطبيب اسيتام لمرضى دون ١٨ سنة وكنت ترغب ف مناقشة ذلك، يرجى الرجوع إلى طبيبك. يتعين عليك ابلاغ طبيبك إذا الاعراض الواردة أعلاه أو تدهور عند تناول مريض دون ١٨ سنة لاسيتام. أيضا، مأمونية العلاج طويلة الأجل فيما يتعلق بالنمو والنضج والتطور المعرف والسلوكي لإسيتام في هذه الفئة العمرية لم يتم إثباتها حتى الان.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>إٍسيتام والأدوية الأخرى</strong></p><p dir="RTL" style="text-align:justify">يرجى إخطار طبيبك أو الصيدلي إذا كنت تتناول أو ستتناول أي أدوية أخرى.</p><p dir="RTL" style="text-align:justify">لا تتناول إسيتام إذا كنت تتناول أدوية لمشاكل في دقات القلب أو أدوية قد تؤثر ف دقات القلب مثل الأدوية الخافضة لارتفاع معدل ضربات القلب المجموعة أ١ أو ٣ ومضادات الأمراض النفسية ( مثل مشتقات فينوثيازين، بيموزيد، وهالوبريدول) مضادات الاكتئاب ثلاثية الحلقات وبعض المضادات للمكروبات (مثل، سبارفلوكساسين، موكسفلوكساسين وإيرثرومايسين ٤ وبنتاميدين وأدوية الملاريا خاصة هالوفانترين) ومضادات الهستامين (استيميزول، ميزولاستين). إذا كان لديك أي اسئلة اخرى حول هذا أسال طبيبك.&nbsp;</p><p dir="RTL" style="text-align:justify">أخبرطبيبك اذا كنت تتناول أي من الأدوية التالية: &nbsp;&nbsp; &nbsp;<br />- مونو أمينو أوكسيديز غير الاختيارية (MAOls) وتشمل فينيليزين وإبرونياريد وأيزوكاربوكسازيد ونيالاميد وترانى ليسيبرومين كمواد فعالة. اذا تناولت أي من هذه الأدوية قد تكون بحاجة للانتظار ١٤ يوما قبل البدء في تناول إسيتام. بعد التوقف من تناول إسيتام يجب ان تنتظر ٧ أيام قبل تناول أي من هذه الأدوية.<br />- مونو أمينو أوكسيديز الاختيارية &laquo;العكسية&raquo; وتشمل موكلوبيميد (ويستخدم لعلاج الاكتئاب) &nbsp;&nbsp; &nbsp;<br />- مونو أمينو أوكسيديز &laquo;الغير عكسية&raquo; وتشمل سيليجلين (يستخدم لعلاج مرض باركنسون). وهذه تزيد من مخاطر الاثار الجانبية. &nbsp;&nbsp; &nbsp;<br />- المضاد الحيوي لينيزولد. &nbsp;&nbsp; &nbsp;<br />- ليثيوم (يستخدم لعلاج الاضطراب الهوس الاكتئابي) وتريبتوفان.&nbsp;&nbsp;<br />- سوماتريبتان والأدوية المشابهة (تستخدم لعلاج الصداع النصفي) وترامادول يستخدم كمضاد للآلام الحادة) وهذه تزيد من مخاطر الاثار الجانبية. &nbsp;&nbsp; &nbsp;<br />- سيميتايدين وأميبرازول (تستخدم لعلاج قرحة المعدة) وفلوفو كسامين (مضاد للاكتئاب) وتيكلوبيدين (يستخدم لتقليل مخاطر الذبحة). هذه قد تتسبب ف زيادة مستوى إسيتام ف الدم.&nbsp;<br />- عشبة القديس وارت ( عشبة الجامعة) - علاج عشبي يستخدم للاكتئاب. &nbsp;&nbsp; &nbsp;<br />- حامض استايلسالسيليك والأدوية الغير استيرويدية المضاده للالتهاب (أدوية تستخدم لتسكين الآلام و ترقيق الدم لذا تسمى مضادة للتخثر).&nbsp;</p><p dir="RTL" style="text-align:justify">- وارفارين وديبريدامول وفينبروكومون (أدوية تستخدم لترقيق الدم لذا تسمى مضادة للتخثر) من المحتمل أن يقوم طبيبك بمراجعة زمن التخثر لدمك عند بدء وإيقاف تناول إسيتام من أجل التحقق من ان جرعة مضاد التخثر لا تزال كافية. &nbsp;&nbsp; &nbsp;<br />- ميلفوكوين (يستخدم لعلاج الملاريا) بويروبيون (يستخدم لعلاج الاكتثاب ولمساعدتك ف الاقلاع عن التدخين) وترامادول (يستخدم لعلاج الالم الحاد) بسبب الخطر المحتمل للبداية المتدنية للأمراض.&nbsp;<br />- مضادات الذهان (أدوية تستخدم لعلاج الشيزوفرينيا والذهان) بسبب الخطر المحتمل للبداية المتدنية الأمراض ومضادات الاكتئاب. &nbsp;&nbsp; &nbsp;<br />- فليكينيد، بروبافينون وميتوبرولول ( يستخدم لامراض القلب والأوعية) ديسيبرامين كلوميبرامين ونوتر بتيلين (مضادات للاكتثاب) وريسبرودين وثيوريدازين وهالوبريدول (مضادات الخلل النفسي). قد يتطلب خفض جرعة إسيتام.&nbsp;<br />- الأدوية التى تطيل ما يطلق عليه (فترة إزالة الاستقطاب وعود الاستقطاب الكهربائى) أو الأدوية التي تخفض مستويات البوتاسيوم والماغنيسيوم في الدم. أطلب النصح من طبيبك لهذه الأدوية.&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>اسيتام مع الطعام والشراب والكحول.</strong></p><p dir="RTL" style="text-align:justify">يمكن تناول اسيتام مع الأكل أو بدونه ( أنظر القسم 3 &quot;كيف تتناول اسيتام&quot;).</p><p dir="RTL" style="text-align:justify">كما هو الحال مع الكثير من الأدوية، فإن الجمع بين اسيتام والكحول لا يُنصح به على الرغم من أنه غير المتوقع أن يتفاعل اسيتام مع الكحول.</p><p dir="RTL" style="text-align:justify"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL" style="text-align:justify">إذا كنتِ حاملا أو مرضعة أو تعتقدين إنك حاملا أو تخطيطين للإنجاب أطلبي النصح من طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL" style="text-align:justify">تأكدي من أن القابلة المولدة و/أو طبيبك يعلم أنك تتناولين اسيتام. عند تناوله أثناء الحمل وبخاصة في آخر 3 شهور من الحمل، فإن الأدوية مثل اسيتام قد تزيد مخاطر ظهور حالة خطيرة في المواليد تسمى استمرار ارتفاع ضغط الدم الرئوي للمواليد تجعل تنفس الطفل سريعا ويبدو مزرقا. تبدأ هذه الأعراض عادة أثناء الـ 24 ساعة الأولى بعد ميلاد الطفل. إذا حدث هذا لطفلك عليك الاتصال القابلة المولدة و/أو طبيبك فورا.</p><p dir="RTL" style="text-align:justify">إذا تناولت اسيتام في آخر 3 شهور من الحمل، يتعين عليك إدراك أن الآثار التالية قد تظهر على طفلك وهي صعوبة في التنفس ولون الجلد الأزرق والنوبات وتغييرات حرارة الجسم وصعوبات التغذية وانخفاض سكر الدم وتصلب او تمدد العضلات وانعكاسات قوية والارتعاش والعصبية والبكاء باستمرار والنعاس وصعوبة النوم. إذا حدث لطفلك أي من هذه الأعراض عليك الاتصال بطبيبك فورا.</p><p dir="RTL" style="text-align:justify">في حالة استخدامه أثناء الحمل يجب عدم إيقاف اسيتام بشكل مفاجئ.</p><p dir="RTL" style="text-align:justify">لا تتناولي اسيتام إذا كنت مرضعة إلا إذا تمت مناقشة الأخطار والفوائد به مع طبيبك.</p><p dir="RTL" style="text-align:justify">أطلب النصح من طبيبك أو الصيدلي إذا كنت تتناول أي أدوية.</p><p dir="RTL" style="text-align:justify"><em>الخصوبة </em></p><p dir="RTL" style="text-align:justify">سيتالوبرام وهو دواء مشابه لاسيتالوبرام والذي أظهر أنه يقلل من جودة الحيوانات المنوية في الدراسات على الحيوانات ونظريا هذا قد يؤثر على الخصوبة ولكن التأثير على خصوبة الإنسان لم تلاحظ بعد.</p><p dir="RTL" style="text-align:justify"><strong>القيادة واستخدام المعدات </strong></p><p dir="RTL" style="text-align:justify">قد يغير هذا الدواء مواعيد التفاعل بشدة حتى عندما يُستخدم حسب الوصف ويتسبب في إضعاف القدرة على القيادة واستخدام المعدات. لا تقم بقيادة السيارة أو تشغيل المعدات حتى تعرف كيف يؤثر اسيتام عليك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">دائما تناول هذا الدواء تماما كما وصفه الطبيب أو الصيدلي . راجع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL" style="text-align:justify"><strong>البالغون: </strong></p><p dir="RTL" style="text-align:justify"><em>لعلاج الاكتئاب</em></p><p dir="RTL" style="text-align:justify">الجرعة الموصى بها من اسيتام هي 10 ملجم يتم تناولها كجرعة يومية واحدة. يمكن زيادة الجرعة بواسطة الطبيب إلى 20 ملجم كحد أقصى في اليوم.</p><p dir="RTL" style="text-align:justify"><em>لعلاج اضطرابات الهوس سواء كان بخوف مرض أو بدونه</em></p><p dir="RTL" style="text-align:justify">&nbsp;الجرعة الأولية لاسيتام هي 5 ملجم يتم تناولها كجرعة يومية واحدة للأسبوع الأول قبل زيادة الجرعة إلى 10 ملجم يميا. يمكن زيادة الجرعة أكثر بواسطة الطبيب إلى 20 ملجم كحد أقصى في اليوم.</p><p dir="RTL" style="text-align:justify"><em>لعلاج اضطرابات القلق الاجتماعي (الخوف الاجتماعي)</em></p><p dir="RTL" style="text-align:justify">الجرعة الموصى بها من اسيتام هي 10 ملجم يتم تناولها كجرعة يومية واحدة. استنادا على استجابتك للعلاج يمكن للطبيب تقليل الجرعة إلى 5 ملجم أو زيادتها إلى 20 ملجم كحد أقصى في اليوم.</p><p dir="RTL" style="text-align:justify"><em>لعلاج اضطرابات الوسواس القهري</em></p><p dir="RTL" style="text-align:justify">الجرعة الموصى بها من اسيتام هي 10 ملجم يتم تناولها كجرعة يومية واحدة. يمكن زيادة الجرعة بواسطة الطبيب إلى 20 ملجم كحد أقصى في اليوم.للعلاج على المدى الطويل فإن فوائد العلاج يجب أن يتم التحقق منها بشكل منتظم.</p><p dir="RTL" style="text-align:justify"><em>المرضى كبار السن (فوق عمر 65 سنة) </em></p><p dir="RTL" style="text-align:justify">الجرعة الأولية الموصى بها من اسيتام هي 5 ملجم يتم تناولها كجرعة يومية واحدة. يمكن زيادة الجرعة بواسطة الطبيب إلى 10 ملجم في اليوم.</p><p dir="RTL" style="text-align:justify">لم تتم دراسة فعالية اسيتام في علاج اضطراب القلق الاجتماعي (الخوف الاجتماعي) في المسنين.</p><p dir="RTL" style="text-align:justify"><em>المرضى الذين لديهم خلل في وظيفة الكبد</em></p><p dir="RTL" style="text-align:justify">الجرعة الأولية الموصى بها من اسيتام للمرضى الذين يعانون من خلل في وظيفة الكبد&nbsp; يجب ألا تتعدى 5 ملجم يوميا في أول 14 يوم. يمكن للطبيب رفع الجرعة اليومية وذلك يعتمد على استجابتك حتى 10 ملجم يوميا. يجب الإشارة إلى أخذ الحذر ومعايرة الجرعة للمرضى الذين لديهم خلل حاد في وظيفة الكبد</p><p dir="RTL" style="text-align:justify"><em>المرضى الذين لديهم خلل في وظيفة الكلى</em></p><p dir="RTL" style="text-align:justify">مع الخلل الخفيف إلى المتوسط في وظيفة الكلى لايحتاج إلى تعديل الجرعة. تمت الإشارة للمرضى الذين لديهم خلل حاد في وظيفة الكلى</p><p dir="RTL" style="text-align:justify"><em>الاستخدام للأطفال والمراهقين (دون سن 18 سنة)&nbsp; </em></p><p dir="RTL" style="text-align:justify">يجب عدم إعطاء اسيتام عادة للأطفال والمراهقين. للمزيد من المعلومات يرجى النظر في القسم 2 &quot; ماذا تريد أن تعرف قبل تناول اسيتام&quot;</p><p dir="RTL" style="text-align:justify">أقراص اسيتام 5 ملجم المغلفة بشريط :</p><p dir="RTL" style="text-align:justify">يرجى تناول الأقراص المغلفة بشريط مرة واحدة في اليوم. تُبلع كلها مع ماء كافي (يُفضل كوب ماء) يمكن تناول اسيتام مع الطعام أو بدونه.</p><p dir="RTL" style="text-align:justify">أقراص اسيتام 15,10 و 20 ملجم المغلفة بشريط :</p><p dir="RTL" style="text-align:justify">يرجى تناول الأقراص المغلفة بشريط مرة واحدة في اليوم. تُبلع كلها مع ماء كافي (يُفضل كوب ماء) يمكن تناول اسيتام مع الطعام أو بدونه.</p><p dir="RTL" style="text-align:justify">عند الضرورة يمكن كسر القرص بوضعه على سطح مستوي وتكون العلامة إلى أعلى. بعدها يمكن كسر القرص بضغطه إلى أسفل على طرفي القرص باستخدام أصبعي السبابة كما مبين في الشكل.</p><p dir="RTL" style="text-align:justify"><strong>مدة العلاج</strong></p><p dir="RTL" style="text-align:justify">قد تأخذ أسبوعين قبل أن تبدأ في الشعور بالتحسن. واصل في تناول اسيتام حتى وإن استغرق ذلك وقتا قبل شعورك بأي تحسن في حالتك. لا تغير جرعات الدواء قبل التحدث إلى طبيبك أولا.</p><p dir="RTL" style="text-align:justify">واصل في تناول اسيتام لأطول مدة حسب توصية طبيبك. إذا أوقفت علاجك مبكرا، قد تعود إليك أعراضك. من الموصى به أن يستمر العلاج لمدة 6 شهور على الأقل عند شعورك بالتحسن مرة أخرى.</p><p dir="RTL" style="text-align:justify"><strong>إذا تناولت اسيتام أكثر من المقرر</strong></p><p dir="RTL" style="text-align:justify">إذا تناولت إسيتام أكثر من المقرر أو إذا تناول شخص آخر دوائك بالخطأ، أبلغ طبيبك أو أذهب إلى المستشفى مباشرة. قم بهذا حتى وإن شعرت أنك جيدا. خذ معك الأقراص المتبقية وكذلك الصندوق/ الوعاء حتى وإن كانت فارغة.</p><p dir="RTL" style="text-align:justify">قد تشمل أعراض الجرعة الزائدة الدوار والارتعاش وعدم الراحة والشعور بالنعاس والسقوط بدون وعي والتغيير في دقات القلب والنوبات وانخفاض التهوية وضعف العضلات والطراوة أو الألم والشعور بالمرض أو ارتفاع درجة الحرارة (انحلال الربيدات) والتغيير في توازن السوائل/الأملاح في الجسم والقيء والمرض.</p><p dir="RTL" style="text-align:justify"><strong>إذا نسيت تناول اسيتام </strong></p><p dir="RTL" style="text-align:justify">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. إذا نسيت تناول جرعة اسيتام، تناول اسيتام كالمعتاد في المرة القادمة.</p><p dir="RTL" style="text-align:justify"><strong>إذا توقفت عن تناول اسيتام </strong></p><p dir="RTL" style="text-align:justify">إذا كنت ترغب في قطع العلاج، يرجى مناقشة ذلك مع طبيبك مسبقا. قد يكون بحاجة لاتخاذ التدابير المناسبة. لا تتوقف عن تناول الدواء بمبادرة منك بدون مناقشة ذلك مع طبيبك. عند إيقاف العلاج باسيتام، فإن طبيبك سوف يقلل الجرعة تدريجيا خلال عدة أسابيع أو شهور. هذا قد يساعد في خفض إمكانية الآثار الإنسحابية.</p><p dir="RTL" style="text-align:justify">عند توقفك عن تناول اسيتام، خصوصا إذا كان فجائيا، قد تشعر بأعراض ذلك التوقف، وهذه شائعة عند توقف العلاج باسيتام. تكون الخطورة عالية إذا تم استخدام اسيتام لمدة طويلة أو بجرعات عالية أو إذا تم خفض الجرعة بشكل سريع. وجد معظم الناس أن الأعراض خفيفة وتختفي لوحدها خلال أسبوعين. ومع ذلك قد تكون شديدة لدى بعض المرضى أو قد تطول مدتها (2-3 أشهر أو أكثر). إذا تعرضت لأعراض توقف حادة عند توقفك عن تناول اسيتام، يرجى التواصل مع طبيبك. قد يطلب منك البدء في تناول الأقراص مرة أخرى والتوقف عنها ببطء.</p><p dir="RTL" style="text-align:justify">أعراض التوقف تشمل: الشعور بالدوار (عدم الثبات أو التوازن) الشعور بوخز الإبر والدبابيس والشعور بالحرقان و(أقل شيوعا) الشعور بصدمة كهربائية تتضمن الرأس وتقطع النوم (الأحلام المزعجة والكوابيس وعدم القدرة على النوم) والشعور بالقلق والصداع والشعور بالإعياء (الغثيان) والتقيؤ والتعرق (بما في ذلك التعرق الليلي) والشعور بالعصبية أو الهيجان والرعاش (الإهتزاز). الشعور بالتشويش أو عدم التكيف الشعور بالعاطفية أو تعكر المزاج والإسهال ( براز محلول) اضطرابات الرؤية و رفرفة أو تقصف ضربات القلب (خفقان).</p><p dir="RTL" style="text-align:justify">إذا كان لديك أسئلة إضافية حول استخدام الدواء، أسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">مثل كافة الأدوية يمكن أن يسبب هذا الدواء آثارا جانبية على الرغم من عدم تعرض كل الناس لها.</p><p dir="RTL" style="text-align:justify">&nbsp;تظهر الآثار الجانبية بصورة أكثر شيوعا في الأسبوع الأول أو الثاني للعلاج وعادة تصبح أقل حدة وأقل تكرارا كلما تواصل العلاج.</p><p dir="RTL" style="text-align:justify"><strong>قابل طبيبك إذا تعرضت لأي من الآثار الجانبية التالية أثناء العلاج: </strong></p><p dir="RTL" style="text-align:justify">غير الشائعة (أكثر من 1 في 1000 شخص وأقل من 1 في 100 شخص):</p><p dir="RTL" style="text-align:justify">نزيف غير معتاد بما في ذلك النزيف المعوي</p><p dir="RTL" style="text-align:justify">نادرة (أكثر من 1 في 10000 شخص وأقل من 1 في 1000 شخص):</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بدأ عليك انتفاخ في الجلد أو اللسان أو الشفاه أو الوجه أو لديك صعوبة في التنفس أو البلع&nbsp; (رد الفعل التحسسي)، تواصل مع طبيبك أو أذهب مباشرة إلى المستشفى</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حمى عالية أو تهيج أو ارتباك أو رجفة وتقلصات مفاجئة في العضلات هذه قد تكون علامات لحالة نادرة تسمى متلازمة السيروتونين(serotonin syndrome).</p><p dir="RTL" style="text-align:justify"><strong>إذا تعرضت إلى الآثار الجانبية التالية يجب أن تتواصل مع طبيبك أو الذهاب مباشرة إلى المستشفى:</strong></p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات مرضية</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد وبياض العيون علامة لخلل وظيفة الكبد / التهاب الكبد الوبائي.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دقات القلب السريعة غير المنتظمة والشحوب التي قد تكون أعراض لحالة مهددة للحياة تسمى لوي النقاط (Torsades de Pointes)</p><p dir="RTL" style="text-align:justify"><strong>بالإضافة لما ذكر أعلاه تم تسجيل الآثار الجانبية التالية: </strong></p><p dir="RTL" style="text-align:justify">شائعة جدا (أكثر من 1 في كل 10 أشخاص)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (الغثيان)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL" style="text-align:justify">شائعة (أكثر من 1 في 100 شخص وأقل من 1 في 10 شخص):</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خوف عام وعدم الراحة والأحلام غير الطبيعية وصعوبة النوم والنعاس والدوار وحساسية الجلد مثل الحرق والثقب والحكة أو الوخز مع عدم وجود سبب جسدي ظاهر أو الرعشة أو التثاؤب.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات الجنسية (تأخير القذف ومشاكل في الانتصاب وضعف القوة الجنسية وقد تجد النساء صعوبة في الوصول إلى النشوة)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال والإمساك والقيء وجفاف الفم</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد أو سيلان الأنف (التهاب الجيوب الأنفية)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإعياء والحمى &nbsp;</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الم المفاصل والعضلات</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص أو زيادة الشهية</p><p dir="RTL" style="text-align:justify">غير شائعة (أكثر من 1 في 1000 شخص وأقل من 1 في 100 شخص):</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صك وقبض الأسنان غير الإرادي والهياج والعصبية والهوس وحالة الارتباك</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب التذوق واضطراب النوم والشحوب</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرحم غير مرتبط بالدورة الشهرية والتدفق غير الطبيعي أو الممتد للدورة الشهرية.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللسع وطفح القراص (الشرى) والطفح الجلدي والحكة</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ اليدين والرجلين</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسيع حدقة العين، عدم وضوح الرؤية، طنين الإذن.</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع دقات القلب</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقصان الوزن</p><p dir="RTL" style="text-align:justify">نادرة (أكثر من 1 في 10000 شخص وأقل من 1 في 1000 شخص):</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوان، تبدد الشخصية والهلوسة</p><p dir="RTL" style="text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء دقات القلب</p><p dir="RTL" style="text-align:justify">بعض المرضى أبلغوا عن (التكرار لا يمكن تقديره من البيانات المتوفرة):</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفكير في إيذاء النفس أو التفكير في قتل النفس ، أنظر أيضا لقسم &quot;التحذيرات والاحتياطات&quot;</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهوس</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الحركة (حركة لا إرادية للعضلات)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدفق الحليب من النساء غير المرضعات</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب مؤلم للقضيب</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النزف بما في ذلك الجلد ونزيف المخاطية (كدمة) وانخفاض مستوى الصفائح الدموية</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار عند الوقوف بسبب تدني ضغط الدم (هبوط ضغط الدم)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم (الأعراض بالشعور بالمرض مع عضلات ضعيفة أو الارتباك)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;زيادة كميات البول الذي يتم إفرازه ( الإفراز غير المناسب للهرمون المضاد لإدرار البول)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اختبار غير طبيعي لوظيفة الكبد (زيادة كميات إنزيمات الكبد في الدم.)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم الفجائي في الجسم والغشاء المخاطي (الأوديما)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأحداث المتعلقة بالانتحار</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على البقاء ساكنا أو بدون حركة والشعور بعدم الراحة المرتبط بزيادة الحركة*</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية*</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير إيقاع القلب ( تسمى طول فترة الاستقطاب &quot;&quot;prolongation of QT interval تم إثباتها بجهاز تخطيط القلب ؛ وهو فحص لتقييم كيفية عمل القلب)</p><p dir="RTL" style="text-align:justify">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تم تسجيل هذه الآثار الجانبية مع العقاقير التي تعمل بنفس طريقة اسيتالوبارم (المكون النشط لاسيتام)</p><p dir="RTL" style="text-align:justify">تمت ملاحظة زيادة مخاطر تهشم العظام &nbsp;في المرضى الذين يتناولون هذا النوع من الأدوية.</p><p dir="RTL" style="text-align:justify">إذا تعرضت لأي آثار جانبية ، تحدث إلى طبيبك أو الصيدلي أو الممرض وهذه تشمل أي آثار جانبية غير مدرجة في هذه النشرة الطبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">أحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL" style="text-align:justify">لا تستخدم هذا الدواء بعد انتهاء صلاحيته والمبينة في الشريط البلاستيكي ووعاء الأقراص والكرتون بعد انتهاء الصلاحية. تاريخ انتهاء الصلاحية يشير إلى لآخر يوم من ذلك الشهر.</p><p dir="RTL" style="text-align:justify">العبوات البلاستيكية : لا تخزنها في درجة حرارة أكثر من 30 درجة مئوية</p><p dir="RTL" style="text-align:justify">يجب عدم التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. أسال الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">المادة الفعالة هي اسيتالوبرام. يحتوي كل قرص مغلف بشريط على 10 ملجم أو 20 ملجم اسيتالوبرام&nbsp; (على شكل أوكسلات).</p><p dir="RTL" style="text-align:justify">المكونات الأخرى هي: لب القرص: سليولوز بلوري مجهري ، سيليكا غروية لامائية ، كروسكارميلوز الصوديوم والتالك وستيرات الماغنيسيوم ، التغليف: هايبروميلوز 6 سي بي ، ثاني أكسيد التيتانيوم (إي 171) وماكروجول 6000.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:justify">اسيتام 10 ملجم: أقراص بيضاوية محدبة من الجانبين مغلف بشريط رقيق (6.4 مم &times; 9.25 مم) مع علامة في أحد الجانبين وعلامات جانبية بعلامة &quot;E&quot; في الجانب الآخر. يمكن تقسيم القرص لنصفين متساويين. اسيتام 20 ملجم: أقراص بيضاوية محدبة من الجانبين مغلف بشريط رقيق (8 مم &times; 11.7 مم) مع علامة في أحد الجانبين وعلامات جانبية بعلامة &quot;E&quot; في الجانب الآخر. يمكن تقسيم القرص لنصفين متساويين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة أجا&nbsp;للصناعات الدوائية&nbsp;المحدودة</p><p dir="RTL">المدينة الصناعية مدن بحائل، شارع رقم 32</p><p dir="RTL">ص.ب. 6979، حائل 55414</p><p>المملكة العربية&nbsp; السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة الطبية بتاريخ 07/2019م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ESCITAM® 10 mg film-coated tablets
ESCITAM® 20 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Escitam 10 mg: Each tablet contains 10 mg escitalopram (as oxalate)
Escitam 20 mg: Each tablet contains 20 mg escitalopram (as oxalate)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Escitam 10 mg: White, oval, biconvex, 6.4 x 9.25 mm film coated tablets, embossed with ‘E 1’ on one side and a score on one face and two sides. The tablet can be divided into equal halves. Escitam 20 mg: White, oval, biconvex, 8 x 11.80 mm film coated tablets embossed with ‘E 2’ on one side and a score on one face and two sides. The tablet can be divided into equal halves.
The 10 mg and 20 mg tablets can be divided into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Treatment of major depressive episodes.</li><li>Treatment of panic disorder with or without agoraphobia.</li><li>Treatment of social anxiety disorder (social phobia).</li><li>Treatment of generalised anxiety disorder.</li><li>Treatment of obsessive-compulsive disorder.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Posology</u><br />Safety of daily doses above 20 mg has not been demonstrated.</p><p style="text-align:justify"><em>Major depressive episodes</em><br />Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.<br />Usually 2-4 weeks are necessary to obtain antidepressant response. After the symptoms resolve, treatment for at least 6 months is required for consolidation of the response.</p><p style="text-align:justify"><em>Panic disorder with or without agoraphobia</em><br />An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg daily. The dose may be further increased, up to a maximum of 20 mg daily, dependent on individual patient response.<br />Maximum effectiveness is reached after about 3 months. The treatment lasts several months.</p><p style="text-align:justify"><em>Social anxiety disorder</em><br />Usual dosage is 10 mg once daily. Usually 2-4 weeks are necessary to obtain symptom relief. The dose may subsequently, depending on individual patient response, be decreased to 5 mg or increased to a maximum of 20 mg daily.<br />Social anxiety disorder is a disease with a chronic course, and treatment for 12 weeks is recommended to consolidate response. Long-term treatment of responders has been studied for 6 months and can be considered on an individual basis to prevent relapse; treatment benefits should be re-evaluated at regular intervals.<br />Social anxiety disorder is a well-defined diagnostic terminology of a specific disorder, which should not be confounded with excessive shyness. Pharmacotherapy is only indicated if the disorder interferes significantly with professional and social activities.<br />The place of this treatment compared to cognitive behavioural therapy has not been assessed. Pharmacotherapy is part of an overall therapeutic strategy.</p><p style="text-align:justify"><em>Generalised anxiety disorder</em><br />Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be increased to a maximum of 20 mg daily.<br />Long-term treatment of responders has been studied for at least 6 months in patients receiving 20 mg daily. Treatment benefits and dose should be re-evaluated at regular intervals (see Section 5.1).</p><p style="text-align:justify"><em>Obsessive-compulsive disorder</em><br />Initial dosage is 10 mg once daily. Depending on the individual patient response, the dose may be increased to a maximum of 20 mg daily.<br />As OCD is a chronic disease, patients should be treated for a sufficient period to ensure that they are symptom free.<br />Treatment benefits and dose should be re-evaluated at regular intervals (see section 5.1).</p><p style="text-align:justify"><em>Elderly patients (&gt; 65 years of age)</em><br />Initial dosage is 5 mg once daily. Depending on individual patient response the dose may be increased to 10 mg daily (see section 5.2).<br />The efficacy of Escitam in social anxiety disorder has not been studied in elderly patients.</p><p style="text-align:justify"><em>Paediatric population</em><br />Escitam should not be used in the treatment of children and adolescents under the age of 18 years (see section 4.4).</p><p style="text-align:justify"><em>Reduced renal function</em><br />Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Caution is advised in patients with severely reduced renal function (CLCR less than 30 ml/min.) (see section 5.2).</p><p style="text-align:justify"><em>Reduced hepatic function</em><br />An initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to 10 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced hepatic function (see section 5.2).</p><p style="text-align:justify"><em>Poor metabolisers of CYP2C19</em><br />For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended. Depending on individual patient response, the dose may be increased to 10 mg daily (see section 5.2).</p><p style="text-align:justify"><em>Discontinuation symptoms seen when stopping treatment</em><br />Abrupt discontinuation should be avoided. When stopping treatment with escitalopram the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of discontinuation symptoms (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p style="text-align:justify"><u>Method of administration</u><br />Escitam is administered as a single daily dose and may be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients, listed in section 6.1.
Concomitant treatment with non-selective, irreversible monoamine oxidase inhibitors (MAO-inhibitors) is contraindicated due to the risk of serotonin syndrome with agitation, tremor, hyperthermia etc. (see section 4.5).
The combination of escitalopram with reversible MAO-A inhibitors (e.g. moclobemide) or the reversible non-selective MAO-inhibitor linezolid is contraindicated due to the risk of onset of a serotonin syndrome (see section 4.5).
Escitalopram is contraindicated in patients with known QT interval prolongation or congenital long QT syndrome.
Escitalopram is contraindicated together with medicinal products that are known to prolong the QT interval (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The following special warnings and precautions apply to the therapeutic class of SSRIs (Selective Serotonin Re-uptake Inhibitors).</p><p style="text-align:justify"><u>Paediatric population</u><br />Escitam should not be used in the treatment of paediatric population. Suicide related behaviours (suicide attempt and suicidal thoughts), and hostility (predominately aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among the paediatric population treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety<br />data in the paediatric population concerning growth, maturation and cognitive and behavioural development are lacking.</p><p style="text-align:justify"><u>Paradoxical anxiety</u><br />Some patients with panic disorder may experience increased anxiety symptoms at the beginning of treatment with antidepressants. This paradoxical reaction usually subsides within two weeks during continued treatment. A low starting dose is advised to reduce the likelihood of an anxiogenic effect (see section 4.2).</p><p style="text-align:justify"><u>Seizures</u><br />Escitalopram should be discontinued if a patient develops seizures for the first time, or if there is an increase in seizure frequency (in patients with a previous diagnosis of epilepsy). SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored.</p><p style="text-align:justify"><u>Mania</u><br />SSRIs should be used with caution in patients with a history of mania/hypomania. SSRIs should be discontinued in any patient entering a manic phase.</p><p style="text-align:justify"><u>Diabetes</u><br />In patients with diabetes, treatment with an SSRI may alter glycaemic control (hypoglycaemia or hyperglycaemia). Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p style="text-align:justify"><u>Suicide/suicidal thoughts or clinical worsening</u><br />Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p style="text-align:justify">Other psychiatric conditions for which Escitam is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p style="text-align:justify">Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta analysis of placebo controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes.</p><p style="text-align:justify">Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p style="text-align:justify"><u>Akathisia/psychomotor restlessness</u><br />The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p style="text-align:justify"><u>Hyponatraemia</u><br />Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported rarely with the use of SSRIs and generally resolves on discontinuation of therapy. Caution should be exercised in patients at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.</p><p style="text-align:justify"><u>Haemorrhage</u><br />There have been reports of cutaneous bleeding abnormalities, such as ecchymoses and purpura, with SSRIs. Caution is advised in patients taking SSRIs, particularly in concomitant use with oral anticoagulants, with medicinal products known to affect platelet function (e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti-inflammatory medicinal products (NSAIDs), ticlopidine and dipyridamole) and in patients with known bleeding tendencies.</p><p style="text-align:justify"><u>ECT (electroconvulsive therapy)</u><br />There is limited clinical experience of concurrent administration of SSRIs and ECT, therefore caution is advisable.</p><p style="text-align:justify"><u>Serotonin syndrome</u><br />Caution is advisable if escitalopram is used concomitantly with medicinal products with serotonergic effects such as sumatriptan or other triptans, tramadol and tryptophan.</p><p style="text-align:justify">In rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with serotonergic medicinal products. A combination of symptoms, such as agitation, tremor, myoclonus and hyperthermia may indicate the development of this condition. If this occurs treatment with the SSRI and the serotonergic medicinal product should be discontinued immediately and symptomatic treatment initiated.</p><p style="text-align:justify"><u>St. John&#39;s wort</u><br />Concomitant use of SSRIs and herbal remedies containing St. John&#39;s wort (Hypericum perforatum) may result in an increased incidence of adverse reactions (see section 4.5).</p><p style="text-align:justify"><u>Discontinuation symptoms seen when stopping treatment</u><br />Discontinuation symptoms when stopping treatment are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials adverse events seen on treatment discontinuation occurred in approximately 25% of patients treated with escitalopram and 15% of patients taking placebo.</p><p style="text-align:justify">The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.</p><p style="text-align:justify">They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.</p><p style="text-align:justify">Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that escitalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see &ldquo;Discontinuation symptoms seen when stopping treatment&rdquo;, section 4.2).</p><p style="text-align:justify"><u>Sexual dysfunction</u><br />Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.</p><p style="text-align:justify"><u>Coronary heart disease</u><br />Due to limited clinical experience, caution is advised in patients with coronary heart disease (see section 5.3).</p><p style="text-align:justify"><u>QT interval prolongation</u><br />Escitalopram has been found to cause a dose-dependent prolongation of the QT interval. Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases (see sections 4.3, 4.5, 4.8, 4.9 and 5.1).</p><p style="text-align:justify">Caution is advised in patients with significant bradycardia; or in patients with recent acute myocardial infarction or uncompensated heart failure.</p><p style="text-align:justify">Electrolyte disturbances such as hypokalaemia and hypomagnesaemia increase the risk for malignant arrhythmias and should be corrected before treatment with escitalopram is started.</p><p style="text-align:justify">If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is started.</p><p style="text-align:justify">If signs of cardiac arrhythmia occur during treatment with escitalopram, the treatment should be withdrawn and an ECG should be performed.</p><p style="text-align:justify"><u>Angle-Closure Glaucoma</u><br />SSRIs including escitalopram may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Escitalopram should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Pharmacodynamic interactions</strong></p><p style="text-align:justify"><u>Contraindicated combinations:</u><br /><strong><em>Irreversible non-selective MAOIs</em></strong><br />Cases of serious reactions have been reported in patients receiving an SSRI in combination with a non-selective, irreversible monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued SSRI treatment and have been started on such MAOI treatment (see section 4.3). In some cases, the patient developed serotonin syndrome (see section 4.8).</p><p style="text-align:justify">Escitalopram is contraindicated in combination with non-selective, irreversible MAOIs. Escitalopram may be started 14 days after discontinuing treatment with an irreversible MAOI. At least 7 days should elapse after discontinuing escitalopram treatment, before starting a non-selective, irreversible MAOI.</p><p style="text-align:justify"><strong><em>Reversible, selective MAO-A inhibitor (moclobemide)</em></strong><br />Due to the risk of serotonin syndrome, the combination of escitalopram with a MAO-A inhibitor such as moclobemide is contraindicated (see section 4.3). If the combination proves necessary, it should be started at the minimum recommended dosage and clinical monitoring should be reinforced.</p><p style="text-align:justify"><strong><em>Reversible, non-selective MAO-inhibitor (linezolid)</em></strong><br />The antibiotic linezolid is a reversible non-selective MAO-inhibitor and should not be given to patients treated with escitalopram. If the combination proves necessary, it should be given with minimum dosages and under close clinical monitoring (see section 4.3).</p><p style="text-align:justify"><strong><em>Irreversible, selective MAO-B inhibitor (selegiline)</em></strong><br />In combination with selegiline (irreversible MAO-B inhibitor), caution is required due to the risk of developing serotonin syndrome. Selegiline doses up to 10 mg/day have been safely co-administered with racemic citalopram.</p><p style="text-align:justify"><strong><em>QT interval prolongation</em></strong><br />Pharmacokinetic and pharmacodynamic studies of escitalopram combined with other medicinal products that prolong the QT interval have not been performed. An additive effect of escitalopram and these medicinal products cannot be excluded. Therefore, co-administration of escitalopram with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, anti-malarial treatment particularly halofantrine), certain antihistamines (e.g. astemizole, mizolastine), is contraindicated.</p><p style="text-align:justify"><u>Combinations requiring precautions for use:</u><br /><em>Serotonergic medicinal products</em><br />Co-administration with serotonergic medicinal products (e.g. tramadol, sumatriptan and other triptans) may lead to serotonin syndrome.</p><p style="text-align:justify"><em>Medicinal products lowering the seizure threshold</em><br />SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold (e.g antidepressants (tricyclics, SSRIs), neuroleptics (phenothiazines, thioxanthenes and butyrophenones), mefloquin, bupropion and tramadol).</p><p style="text-align:justify"><em>Lithium, tryptophan</em><br />There have been reports of enhanced effects when SSRIs have been given together with lithium or tryptophan, therefore concomitant use of SSRIs with these medicinal products should be undertaken with caution.</p><p style="text-align:justify"><em>St. John&#39;s wort</em><br />Concomitant use of SSRIs and herbal remedies containing St. John&acute;s wort (Hypericum perforatum) may result in an increased incidence of adverse reactions (see section 4.4).</p><p style="text-align:justify"><em>Haemorrhage</em><br />Altered anti-coagulant effects may occur when escitalopram is combined with oral anticoagulants. Patients receiving oral anticoagulant therapy should receive careful coagulation monitoring when escitalopram is started or stopped (see section 4.4). Concomitant use of non-steriodal anti-inflammatory drugs (NSAIDs) may increase bleeding-tendency (see section 4.4).</p><p style="text-align:justify"><em>Alcohol</em><br />No pharmacodynamic or pharmacokinetic interactions are expected between escitalopram and alcohol. However, as with other psychotropic medicinal products, the combination with alcohol is not advisable.</p><p style="text-align:justify"><em>Medicinal products inducing hypokalaemia/hypomagnesaemia</em><br />Caution is warranted for concomitant use of hypokalaemia/hypomagnesaemia inducing medicinal products as these conditions increase the risk of malignant arrhythmias (see section 4.4).</p><p style="text-align:justify"><strong>Pharmacokinetic interactions</strong></p><p style="text-align:justify"><u>Influence of other medicinal products on the pharmacokinetics of escitalopram</u><br />The metabolism of escitalopram is mainly mediated by CYP2C19. CYP3A4 and CYP2D6 may also contribute to the metabolism although to a smaller extent. The metabolism of the major metabolite S-DCT (demethylated escitalopram) seems to be partly catalysed by CYP2D6.</p><p style="text-align:justify">Co-administration of escitalopram with omeprazole 30 mg once daily (a CYP2C19 inhibitor) resulted in moderate (approximately 50%) increase in the plasma concentrations of escitalopram.</p><p style="text-align:justify">Co-administration of escitalopram with cimetidine 400 mg twice daily (moderately potent general enzyme-inhibitor) resulted in a moderate (approximately 70%) increase in the plasma concentrations of escitalopram. Caution is advised when administering escitalopram in combination with cimetidine. Dose adjustment may be warranted.</p><p style="text-align:justify">Thus, caution should be exercised when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, esomeprazole, fluconazole, fluvoxamine, lansoprazole, ticlopidine) or cimetidine. A reduction in the dose of escitalopram may be necessary based on monitoring of side-effects during concomitant treatment (see section 4.4).</p><p style="text-align:justify"><u>Effect of escitalopram on the pharmacokinetics of other medicinal products</u><br />Escitalopram is an inhibitor of the enzyme CYP2D6. Caution is recommended when escitalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted.</p><p style="text-align:justify">Co-administration with desipramine or metoprolol resulted in both cases in a twofold increase in the plasma levels of these two CYP2D6 substrates.</p><p style="text-align:justify">In vitro studies have demonstrated that escitalopram may also cause weak inhibition of CYP2C19. Caution is recommended with concomitant use of medicinal products that are metabolised by CYP2C19.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Pregnancy</u><br />For escitalopram only limited clinical data are available regarding exposed pregnancies.</p><p style="text-align:justify">Animal studies have shown reproductive toxicity (see section 5.3). Escitam should not be used during pregnancy unless clearly necessary and only after careful consideration of the risk/benefit.</p><p style="text-align:justify">Neonates should be observed if maternal use of Escitam continues into the later stages of pregnancy, particularly in the third trimester. Abrupt discontinuation should be avoided during pregnancy.</p><p style="text-align:justify">The following symptoms may occur in the neonate after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either serotonergic effects or discontinuation symptoms. In a majority of instances the complications begin immediately or soon (&lt;24 hours) after delivery.</p><p style="text-align:justify">Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p style="text-align:justify"><u>Breast-feeding</u><br />It is expected that escitalopram will be excreted into human milk.<br />Consequently, breast-feeding is not recommended during treatment.</p><p style="text-align:justify"><u>Fertility</u><br />Animal data have shown that citalopram may affect sperm quality (see section 5.3). Human case reports with some SSRIs have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Although escitalopram has been shown not to affect intellectual function or psychomotor performance, any psychoactive medicinal product may impair judgement or skills. Patients should be cautioned about the potential risk of an influence on their ability to drive a car and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and frequency with continued treatment.</p><p style="text-align:justify"><u>Tabulated list of adverse reactions</u><br />Adverse reactions known for SSRIs and also reported for escitalopram in either placebo-controlled clinical studies or as spontaneous post-marketing events are listed below by system organ class and frequency.</p><p style="text-align:justify">Frequencies are taken from clinical studies; they are not placebo-corrected. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), or not known (cannot be estimated from the available data).</p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:justify"><strong>System Organ Class</strong></td><td style="text-align:justify"><strong>Frequency</strong></td><td style="text-align:justify"><strong>Undesirable Effect</strong></td></tr><tr><td style="text-align:justify">Blood and lymphatic system disorders</td><td style="text-align:justify">Not known</td><td style="text-align:justify">Thrombocytopenia</td></tr><tr><td style="text-align:justify">Immune system disorders</td><td style="text-align:justify">Rare</td><td style="text-align:justify">Anaphylactic reaction</td></tr><tr><td style="text-align:justify">Endocrine disorders</td><td style="text-align:justify">Not known</td><td style="text-align:justify">Inappropriate ADH secretion</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">Metabolism and nutrition disorders</td><td style="text-align:justify">Common</td><td style="text-align:justify">Decreased appetite, increased appetite, weight increased</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Weight decreased</td></tr><tr><td style="text-align:justify">Not known</td><td style="text-align:justify">Hyponatraemia, anorexia<sup>1</sup></td></tr><tr><td rowspan="4" colspan="1" style="text-align:justify">Psychiatric disorders</td><td style="text-align:justify">Common</td><td style="text-align:justify">Anxiety, restlessness, abnormal dreams<br />libido decreased<br />Female: anorgasmia</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Bruxism, agitation, nervousness, panic attack, confusional state</td></tr><tr><td style="text-align:justify">Rare</td><td style="text-align:justify">Aggression, depersonalisation, hallucination</td></tr><tr><td style="text-align:justify">Not known</td><td style="text-align:justify">Mania, suicidal ideation, suicidal behaviour2</td></tr><tr><td rowspan="5" colspan="1" style="text-align:justify">Nervous system disorders</td><td style="text-align:justify">Very common</td><td style="text-align:justify">Headache</td></tr><tr><td style="text-align:justify">Common</td><td style="text-align:justify">Insomnia, somnolence, dizziness, paraesthesia, tremor</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Taste disturbance, sleep disorder, syncope</td></tr><tr><td style="text-align:justify">Rare</td><td style="text-align:justify">Serotonin syndrome</td></tr><tr><td style="text-align:justify">Not known</td><td style="text-align:justify">Dyskinesia, movement disorder, convulsion, psychomotor restlessness/akathisia<sup>1</sup></td></tr><tr><td style="text-align:justify">Eye disorders</td><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Mydriasis, visual disturbance</td></tr><tr><td style="text-align:justify">Ear and labyrinth disorders</td><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Tinnitus</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">Cardiac disorders</td><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Tachycardia</td></tr><tr><td style="text-align:justify">Rare</td><td style="text-align:justify">Bradycardia</td></tr><tr><td style="text-align:justify">Not known</td><td style="text-align:justify">Electrocardiogram QT prolonged Ventricular arrhythmia including torsade de pointes</td></tr><tr><td style="text-align:justify">Vascular disorders</td><td style="text-align:justify">Not known</td><td style="text-align:justify">Orthostatic hypotension</td></tr><tr><td rowspan="2" colspan="1" style="text-align:justify">Respiratory, thoracic and mediastinal disorders</td><td style="text-align:justify">Common</td><td style="text-align:justify">Sinusitis, yawning</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Epistaxis</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">Gastrointestinal disorders</td><td style="text-align:justify">Very common</td><td style="text-align:justify">Nausea</td></tr><tr><td style="text-align:justify">Common</td><td style="text-align:justify">Diarrhoea, constipation, vomiting, dry mouth</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Gastrointestinal haemorrhages (including rectal haemorrhage)</td></tr><tr><td style="text-align:justify">Hepatobiliary disorders</td><td style="text-align:justify">Not known</td><td style="text-align:justify">Hepatitis, liver function test abnormal</td></tr><tr><td rowspan="3" colspan="1" style="text-align:justify">Skin and subcutaneous tissue disorders</td><td style="text-align:justify">Common</td><td style="text-align:justify">Sweating increased</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Urticaria, alopecia, rash, pruritus</td></tr><tr><td style="text-align:justify">Not known</td><td style="text-align:justify">Ecchymosis, angioedemas</td></tr><tr><td colspan="1" style="text-align:justify">Musculoskeletal and connective tissue disorders</td><td style="text-align:justify">Common</td><td style="text-align:justify">Arthralgia, myalgia</td></tr><tr><td colspan="1" style="text-align:justify">Renal and urinary disorders</td><td style="text-align:justify">Not known</td><td style="text-align:justify">Urinary retention</td></tr><tr><td colspan="1" rowspan="3" style="text-align:justify">Reproductive system and breast disorders</td><td style="text-align:justify">Common</td><td style="text-align:justify">Male: ejaculation disorder, impotence</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Female: metrorrhagia, menorrhagia</td></tr><tr><td style="text-align:justify">Not known</td><td style="text-align:justify">Galactorrhoea<br />Male: priapism</td></tr><tr><td colspan="1" rowspan="2" style="text-align:justify">General disorders and administration site conditions</td><td style="text-align:justify">Common</td><td style="text-align:justify">Fatigue, pyrexia</td></tr><tr><td style="text-align:justify">Uncommon</td><td style="text-align:justify">Oedema</td></tr></tbody></table><p style="text-align:justify"><sup>1 </sup>These events have been reported for the therapeutic class of SSRIs.<br /><sup>2</sup> Cases of suicidal ideation and suicidal behaviours have been reported during escitalopram therapy or early after treatment discontinuation (see section 4.4).</p><p style="text-align:justify"><u>QT interval prolongation</u><br />Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of female gender, with hypokalaemia, or with pre-existing QT interval prolongation or other cardiac diseases (see sections 4.3, 4.4, 4.5, 4.9 and 5.1).</p><p style="text-align:justify"><u>Class effects</u><br />Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p style="text-align:justify"><u>Discontinuation symptoms seen when stopping treatment</u><br />Discontinuation of SSRIs/SNRIs (particularly when abrupt) commonly leads to discontinuation symptoms. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when escitalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section 4.2 and 4.4).</p><p style="text-align:justify"><strong>Reporting of suspected adverse reactions</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.<br /><strong>Saudi Arabia:</strong></p><p style="text-align:justify">- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li style="text-align:justify">Fax: +966-11-205-7662</li><li style="text-align:justify">SFDA Call Center: 19999</li><li style="text-align:justify">E-mail: npc.drug@sfda.gov.sa</li><li style="text-align:justify">&nbsp;Website: www.sfda.gov.sa/npc</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Toxicity</u><br />Clinical data on escitalopram overdose are limited and many cases involve concomitant overdoses of other drugs. In the majority of cases mild or no symptoms have been reported. Fatal cases of escitalopram overdose have rarely been reported with escitalopram alone; the majority of cases have involved overdose with concomitant medications. Doses between 400 and 800 mg of escitalopram alone have been taken without any severe symptoms.</p><p style="text-align:justify"><u>Symptoms</u><br />Symptoms seen in reported overdose of escitalopram include symptoms mainly related to the central nervous system (ranging from dizziness, tremor, and agitation to rare cases of serotonin syndrome, convulsion, and coma), the gastrointestinal system (nausea/vomiting), and the cardiovascular system (hypotension, tachycardia, QT interval prolongation, and arrhythmia) and electrolyte/fluid balance conditions (hypokalaemia, hyponatraemia).</p><p style="text-align:justify"><u>Management</u><br />There is no specific antidote. Establish and maintain an airway, ensure adequate oxygenation and respiratory function. Gastric lavage and the use of activated charcoal should be considered. Gastric lavage should be carried out as soon as possible after oral ingestion. Cardiac and vital signs monitoring are recommended along with general symptomatic supportive measures.</p><p style="text-align:justify">ECG monitoring is advised in case of overdose in patients with congestive heart failure/bradyarrhythmias, in patients using concomitant medications that prolong the QT interval, or in patients with altered metabolism, e.g. liver impairment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: antidepressants, selective serotonin reuptake inhibitors</p><p style="text-align:justify">ATC-code: N 06 AB 10</p><p style="text-align:justify"><u>Mechanism of action</u><br />Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake with high affinity for the primary binding site. It also binds to an allosteric site on the serotonin transporter, with a 1000 fold lower affinity.</p><p style="text-align:justify">Escitalopram has no or low affinity for a number of receptors including 5-HT1A, 5-HT2, DA D1 and D2 receptors, &alpha;1-, &alpha;2-, &beta;-adrenoceptors, histamine H1, muscarine cholinergic, benzodiazepine, and opioid receptors.<br />The inhibition of 5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and clinical effects of escitalopram.</p><p style="text-align:justify"><u>Pharmacodynamic effects</u><br />In a double-blind, placebo-controlled ECG study in healthy subjects, the change from baseline in QTc (Fridericia-correction) was 4.3 ms (90% CI: 2.2, 6.4) at the 10 mg/day dose and 10.7 ms<br />(90% CI: 8.6, 12.8) at the supratherapeutic dose 30 mg/day (see sections 4.3, 4.4, 4.5, 4.8 and 4.9).</p><p style="text-align:justify"><u>Clinical efficacy</u></p><p style="text-align:justify"><em>Major depressive episodes</em><br />Escitalopram has been found to be effective in the acute treatment of major depressive episodes in three out of four double-blind, placebo controlled short-term (8-week) studies. In a long-term relapse prevention study, 274 patients who had responded during an initial 8-week open label treatment phase with escitalopram 10 or 20 mg/day, were randomised to continuation with escitalopram at the same dose, or to placebo, for up to 36 weeks. In this study, patients receiving continued escitalopram experienced a significantly longer time to relapse over the subsequent 36 weeks compared to those receiving placebo.</p><p style="text-align:justify"><em>Social anxiety disorder</em><br />Escitalopram was effective in both three short-term (12- week) studies and in responders in a 6-month relapse prevention study in social anxiety disorder. In a 24-week dose-finding study, efficacy of 5, 10 and 20 mg escitalopram has been demonstrated.</p><p style="text-align:justify"><em>Generalised anxiety disorder</em><br />Escitalopram in doses of 10 and 20 mg/day was effective in four out of four placebo-controlled studies.</p><p style="text-align:justify">In pooled data from three studies with similar design comprising 421 escitalopram-treated patients and 419 placebo-treated patients there were 47.5% and 28.9% responders respectively and 37.1% and 20.8% remitters. Sustained effect was seen from week 1.</p><p style="text-align:justify">Maintenance of efficacy of escitalopram 20mg/day was demonstrated in a 24 to 76 week, randomised, maintenance of efficacy study in 373 patients who had responded during the initial 12-week open-label treatment.</p><p style="text-align:justify"><em>Obsessive-compulsive disorder</em><br />In a randomised, double-blind, clinical study, 20 mg/day escitalopram separated from placebo on the Y-BOCS total score after 12 weeks. After 24 weeks, both 10 and 20 mg/day escitalopram were superior as compared to placebo.</p><p style="text-align:justify">Prevention of relapse was demonstrated for 10 and 20 mg/day escitalopram in patients who responded to escitalopram in a 16-week open-label period and who entered a 24-week, randomised, double-blind, placebo controlled period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Absorption</u><br />Absorption is almost complete and independent of food intake. (Mean time to maximum concentration (mean Tmax) is 4 hours after multiple dosing).<br />As with racemic citalopram, the absolute bioavailability of escitalopram is expected to be about 80%.</p><p style="text-align:justify"><u>Distribution</u><br />The apparent volume of distribution (Vd,&beta;/F) after oral administration is about 12 to 26 L/kg. The plasma protein binding is below 80% for escitalopram and its main metabolites.</p><p style="text-align:justify"><u>Biotransformation</u><br />Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Both of these are pharmacologically active. Alternatively, the nitrogen may be oxidised to form the N-oxide metabolite. Both parent substance and metabolites are partly excreted as glucuronides. After multiple dosing the mean concentrations of the demethyl and didemethyl metabolites are usually 28-31% and &lt;5%, respectively, of the escitalopram concentration. Biotransformation of escitalopram to the demethylated metabolite is mediated primarily by CYP2C19. Some contribution by the enzymes CYP3A4 and CYP2D6 is possible.</p><p style="text-align:justify"><u>Elimination</u><br />The elimination half-life (t&frac12; &beta;) after multiple dosing is about 30 hours and the oral plasma clearance (Cloral) is about 0.6 L/min. The major metabolites have a significantly longer half-life. Escitalopram and major metabolites are assumed to be eliminated by both the hepatic (metabolic) and the renal routes, with the major part of the dose excreted as metabolites in the urine.</p><p style="text-align:justify"><u>Linearity</u><br />There is linear pharmacokinetics. Steady-state plasma levels are achieved in about 1 week. Average steady-state concentrations of 50 nmol/L (range 20 to 125 nmol/L) are achieved at a daily dose of 10 mg.</p><p style="text-align:justify"><u>Elderly patients (&gt; 65 years)</u><br />Escitalopram appears to be eliminated more slowly in elderly patients compared to younger patients. Systemic exposure (AUC) is about 50 % higher in elderly compared to young healthy volunteers (see section 4.2).</p><p style="text-align:justify"><u>Reduced hepatic function</u><br />In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of escitalopram was about twice as long and the exposure was about 60% higher than in subjects with normal liver function (see section 4.2).</p><p style="text-align:justify"><u>Reduced renal function</u><br />With racemic citalopram, a longer half-life and a minor increase in exposure have been observed in patients with reduced kidney function (CLcr 10-53 ml/min). Plasma concentrations of the metabolites have not been studied, but they may be elevated (see section 4.2).</p><p style="text-align:justify"><u>Polymorphism</u><br />It has been observed that poor metabolisers with respect to CYP2C19 have twice as high a plasma concentration of escitalopram as extensive metabolisers. No significant change in exposure was observed in poor metabolisers with respect to CYP2D6 (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No complete conventional battery of preclinical studies was performed with escitalopram since the bridging toxicokinetic and toxicological studies conducted in rats with escitalopram and citalopram showed a similar profile. Therefore, all the citalopram information can be extrapolated to escitalopram.</p><p style="text-align:justify">In comparative toxicological studies in rats, escitalopram and citalopram caused cardiac toxicity, including congestive heart failure, after treatment for some weeks, when using dosages that caused general toxicity. The cardiotoxicity seemed to correlate with peak plasma concentrations rather than to systemic exposures (AUC). Peak plasma concentrations at no-effect-level were in excess (8-fold) of those achieved in clinical use, while AUC for escitalopram was only 3- to 4-fold higher than the exposure achieved in clinical use. For citalopram AUC values for the S-enantiomer were 6- to 7-fold higher than exposure achieved in clinical use. The findings are probably related to an exaggerated influence on biogenic amines i.e. secondary to the primary pharmacological effects, resulting in haemodynamic effects (reduction in coronary flow) and ischaemia. However, the exact mechanism of cardiotoxicity in rats is not clear. Clinical experience with citalopram, and the clinical trial experience with escitalopram, do not indicate that these findings have a clinical correlate.</p><p style="text-align:justify">Increased content of phospholipids has been observed in some tissues e.g. lung, epididymides and liver after treatment for longer periods with escitalopram and citalopram in rats. Findings in the epididymides and liver were seen at exposures similar to that in man. The effect is reversible after treatment cessation. Accumulation of phospholipids (phospholipidosis) in animals has been observed in connection with many cationic amphiphilic medicines. It is not known if this phenomenon has any significant relevance for man.</p><p style="text-align:justify">In the developmental toxicity study in the rat embryotoxic effects (reduced foetal weight and reversible delay of ossification) were observed at exposures in terms of AUC in excess of the exposure achieved during clinical use. No increased frequency of malformations was noted. A pre- and postnatal study showed reduced survival during the lactation period at exposures in terms of AUC in excess of the exposure achieved during clinical use.</p><p style="text-align:justify">Animal data have shown that citalopram induces a reduction of fertility index and pregnancy index, reduction in implantation number and abnormal sperm at exposure well in excess of human exposure. No animal data related to this aspect are available for escitalopram.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />Microcrystalline cellulose, colloidal anhydrous silica, talc, croscarmellose sodium, magnesium stearate.</p><p>Coating:<br />Hypromellose, macrogol 400, titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Escitam 10 mg: White, oval, biconvex, 6.4 x 9.25 mm film coated tablets, embossed with &lsquo;E 1&rsquo; on one side and a score on one face and two sides.The tablet can be divided into equal halves.Escitam 20 mg: White, oval, biconvex, 8 x 11.80 mm film coated tablets embossed with &lsquo;E 2&rsquo; on one side and a score on one face and two sides. The tablet can be divided into equal halves.Escitam is obtainable in blister packs of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd.
Hail Industrial City MODON, Street No 32
PO Box 6979, Hail 55414
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 June 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>